Pharis Biotec (Germany)

Discovery and Characterization of an Endogenous CXCR4 Antagonist

Onofrio Zirafi, Kyeong-Ae Kim, Ludger Ständker et al. · Cell Reports · 2015 · 98 citations · Full text

Endogenous Cxcr4 Antagonist, Medicine, Mechanism Of Action +3

Short-Term Monotherapy in HIV-Infected Patients with a Virus Entry Inhibitor Against the gp41 Fusion Peptide

Wolf‐Georg Forssmann, Yu-Han The, Matthias Stoll et al. · Science Translational Medicine · 2010 · 84 citations

Immunology, Immunodominance, Peptide Science +18

A natural point mutation changes both target selectivity and mechanism of action of sea anemone toxins

Steve Peigneur, László Béress, Carolina Möller et al. · The FASEB Journal · 2012 · 83 citations

Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer

Suresh S. Ramalingam, Normand Blais, Julien Mazières et al. · Clinical Cancer Research · 2016 · 81 citations · Full text

Immunotherapy of patients with hormone‐refractory prostate carcinoma pre‐treated with interferon‐gamma and vaccinated with autologous PSA‐peptide loaded dendritic cells—A pilot study

Bernd Hildenbrand, Brian C. Sauer, O. Kalis et al. · The Prostate · 2007 · 56 citations